Healthcare
Biopharma opportunities and macro challenges: A check-up on the industry
The biopharma industry is excited about anti-obesity drugs, neurology, and AI, but high rates and patent expirations have dampened investor enthusiasm. Where are the biggest opportunities now? Goldman Sachs Research’s Asad Haider, Chris Shibutani, and Salveen Richter discuss on the sidelines of our 45th Annual Global Healthcare Conference.
Related Tags
Subscribe to Briefings
Our weekly newsletter delivers the latest insights on economic forces shaping markets—from Goldman Sachs leaders, economists, and investors around the world.
By submitting this information, you agree that the information you are providing is subject to Goldman Sachs’ Privacy Policy and Terms of Use. You consent to receive our newsletter via email.